[Management of patients developing acute gastro-intestinal graft-versus-host-disease: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

Autor:	de Berranger E; CHU de Lille, service d'hématologie pédiatrique, avenue Eugène-Avinée, 59037 Lille cedex, France. Electronic address: eva.deberranger@chru-lille.fr., Charbonnier A; CHU d'Amiens, groupe hospitalier Amiens Sud, hématologie clinique et thérapie cellulaire, 80034 Amiens cedex 1, France., Davy E; CHU d'Angers, unité protégée, hématologie, 4, rue Larrey, 49100 Angers, France., Dendonker C; CHU de Lille, service nutrition, avenue Oscar-Lambret, 59000 Lille, France., Denis V; CHU de Rouen, service d'onco-hématologie pédiatrie, 1, rue de Germont, 76000 Rouen, France., Desmier D; CHU de Poitiers, onco-hématologie clinique et thérapie cellulaire, 2, rue de la Milétrie, 86000 Poitiers, France., Farrugia C; CHU de Montpellier Saint-Éloi, service onco-hématologie, 80, avenue Augustin-Fliche, 34000 Montpellier, France., Guenounou S; Institut universitaire du cancer de Toulouse Oncopole, service d'hématologie, 1, avenue Irène-Joliot-Curie, 31000 Toulouse, France., Guilbert Y; Institut Paoli-Calmettes, 232, boulevard de Sainte-Marguerite, 13009 Marseille, France., Jost E; University Hospital RWTH Aachen, Pauwelsstraße 30, 52074 Aix-La-Chapelle, Allemagne., L'hostette A; CHU d'ADV Montpellier, service onco-hématologie pédiatrique, 371, avenue du doyen Gaston-Guiraud, 34000 Montpellier, France., Rialland F; Service d'onco-hématologie pédiatrique, HME, 7, quai Moncousu, 44093 Nantes cedex 01, France., Taque S; CHU de Rennes, département de pédiatrie, 16, boulevard de Bulgarie, 35000 Rennes, France., Yafour N; Établissement hospitalier et universitaire 1(er) novembre 1954, service d'hématologie et de thérapie cellulaire, BP 4166, 31000 Ibn-Rochd, Oran, Algérie; Université d'Oran 1, Ahmed-Ben-Bella, faculté de médecine, Oran, Algérie., Seguy D; Université de Lille, CHU de Lille, service endocrinologie, diabétologie, maladies métaboliques et nutrition, LIRIC, Inserm U995, 59000 Lille, France., Yakoub Agha I; Université de Lille, CHU de Lille, Inserm U1286, Infinite, 59000 Lille, France.
Jazyk:	francouzština
Zdroj:	Bulletin du cancer [Bull Cancer] 2021 Dec; Vol. 108 (12S), pp. S30-S38. Date of Electronic Publication: 2021 May 07.
DOI:	10.1016/j.bulcan.2021.01.013
Abstrakt:	Graft-versus-host disease (GVHD) is the most common complication after allogeneic hematopoietic cell transplantation (allo-HCT) with a frequency range of 30% to 50%. GVH is the leading cause of non-relapse-related deaths and a cause early mortality. Gastro-intestinal (GI) GVH results in digestive manifestations that involve the small intestine and the colon. The patient may then have diarrhea, intestinal bleeding, abdominal pain but also clinical signs such as nausea and vomiting may lead to anorexia. GI-GVHD promotes undernutrition as well as significant losses of vitamins and trace elements. In the case of post-transplant diarrhea, differential diagnosis can include GI-GVHD, infection and drug toxicity. Although, corticosteroids w/wo calcineurin inhibitors represent the standard of care in first line treatment, there is no consensus regarding salvage therapy in case of corticoresistant GI-GVH. In addition, assessment of early nutritional status would help combating undernutrition, which is an independent risk factor for mortality in patients with GI-GVHD. In this workshop of the Fancophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) we focused on the management of patients developing GI-GVHD following allo-HCT. (Copyright © 2021 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu